Page 11 - Vasoclick emagazine Issue2
P. 11

Vasoclick, Edition 2                                                                                 10



        Systematic Review & Meta-analysis

        Association of Psoriasis with Incident Venous Thromboembolism and Peripheral
        Vascular Disease


        Endorsed by: Dr. Rajesh Hyderabadi, Cardio-Thoracic Surgeon, Ahmedabad.


        Background

           Psoriasis is a chronic inflammatory disease of the skin and increases the risk of cardiovascular
           disease (CV) by 50%, rising further with skin severity. 1

           Psoriasis  shares similar  inflammatory pathways and mechanisms  as that of venous
           thromboembolism (VTE) and peripheral vascular disease (PVD).      2

           The previous meta-analyses that aimed to identify the association between them could not draw a
           definitive conclusion due to the small number and cross-sectional nature of the studies included.    2

           The current psoriasis  guidelines discuss  the cardiovascular  comorbidities  of psoriasis  but
           sufficient information is not available on its association with VTE and PVD.  3

           The comprehensive meta-analysis  study  by Chen  et al aims  to compile  and review the current
           inconsistent  evidence  on the association  of psoriasis  with VTE and  PVD  to provide  a  better

           understanding of the outcomes of recent studies.   2




        Methods:                                                 associations of psoriasis with VTE or PVD.
        This  review and meta-analysis  followed the             Had an exposure group that had patients with

        Meta-analysis of Observational Studies in                psoriasis and a non-exposure group that had
        Epidemiology (MOOSE)  reporting guideline                patients without psoriasis.
                                   4
        group19  and  the  Preferred  Reporting Items for        Reported the risk  estimates  of VTE and/or
        Systematic      Reviews     and     Meta-analyses        PVD.

        (PRISMA)  reporting 2020 guideline.                      Studies with confirmed clinical diagnoses of
                   5
                                                                 psoriasis, VTE, and PVD.

           Data Sources:
           MEDLINE, Embase, Cochrane Library, Web of             Studies excluded:

           Science, and the Cumulative Index to Nursing          Cross-sectional studies, case-control studies,
           and Allied Health Literature were searched for        case reports,  editorials,  review articles,  and

           publications that studied the associations of         nonhuman studies were excluded.     2
           psoriasis  with VTE or PVD  from their

           respective inception to May 21, 2021.  2              Data Extraction:
                                                                 First  author,  year of  publication,  country,

           Study Selection Criteria:                             database, study period, patient characteristics
           Cohort     studies     that    examined      the      (sample size, mean age, and sex), definition of




















 psoriasis, and outcomes of interest (VTE and   There were 9 (69.2%) studies  that reported   The pooled risk  estimates  differed with   incident  VTE in  patients  with psoriasis  but

 PVD). 2  HR or SIR and were selected for quantitative   geographic locations,  with studies  done  in   not in the US (Table 1).
 2
 The adjusted risk estimates, including hazard   meta-analysis (Figure 1).  Asia and Europe showing an increased risk of

 ratios  (HRs),  risk  ratios  (RRs),  and
 standardized incidence ratios (SIRs), with 95%

 confidence intervals (CIs). 2



 Data Synthesis:
 The meta-analyses  were conducted  using

 Review Manager version 5.4.1 (The Cochrane
 Collaboration),  and  Stata,  version  17

 (StataCorp). A P value of <0.05 was defined as
 statistically significant. 2

 HRs and SIRs were used for meta-analysis to
 analyse risk  for  the entire study  period. The

 adjusted risk  estimates  of subgroups  were
 pooled when overall effects  were not

 available. 2
 Crude risk estimates with 95% CI were

 calculated when not available in the studies. 2
 I  statistic was used to quantify between-study  Risk for Incident VTE:
 2
 heterogeneity with I >50% indicating moderate   Based  on the  9 studies (12,052,781
 2
 heterogeneity. 2  participants)  examined,  patients  with

 psoriasis  had  a 1.26-fold  increased  risk  for
 Results:  incident  VTE than those without  psoriasis

 Study  Selection  and  their  characteris-  (pooled HR, 1.26; 95%, CI 1.08-1.48; I  = 93%)
 2
 tics:  (Figure 2). 2
 A total of 1836 records were retrieved from

 the literature search, 13 cohort studies   The  association  remained  significant  in
 (12,435,982 participants) out of which were   patients  with psoriatic  arthritis  but  did not

 selected for qualitative review (Figure 1).  increase  significantly  in  patients  with
 psoriasis alone (Table 1). 2

 Out of the 13 studies  selected, 9 (69.2%)
 reported the risk estimates of incident VTE,   The studies  done on  women showed an

 and 4 (30.8%) reported the risk estimates of   increased risk for VTE as opposed to those

 incident PVD (Figure 1).  done on men(Table 1). 2
   6   7   8   9   10   11   12   13   14   15   16